IQVIA HOLDINGS INC.
No SEC Form 4 filings for $IQV in the last 30 days.
See all $IQV insider activity →Iqvia Holdings (IQV), a healthcare services company for drugmakers, has risen 79% since its April low. The stock, up 18.8% YTD, reports Q3 earnings on Oct. 27. Analysts discuss AI's impact, growth prospects, and technical indicators.
Azenta reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B revenue, up 8.7% YoY, exceeding expectations. UFP Technologies reported $174M revenue, up 15.1% YoY, with the largest analyst estimate beat. West Pharmaceutical Services reported $872.3M revenue, up 13.8% YoY, topping expectations. All stocks have seen post-earnings gains.
Stifel raised its price target for IQVIA (NYSE:IQV) to $303 from $276, citing an improving market backdrop and strong company performance. The stock is near its 52-week high and has surged 48.72% over the past six months. Multiple analysts have raised their price targets and maintained buy ratings, highlighting IQVIA's growth prospects and strong data infrastructure.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning IQV (IQVIA HOLDINGS INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent IQV coverage spans financial news, earnings and technology.
Potential upside if Q3 results exceed guidance; downside risk if guidance is weak.
Post‑earnings price rally
Analyst upgrade with a higher price target is likely to support the stock.
Analyst target increase signals improved outlook for IQVIA.
The fine and corrective order likely pressure IQVIA's share price lower as investors assess compliance costs and reputational risk.
AlphAI scores every news story that mentions IQV with an AI model for sentiment and relevance, and aggregates insider trades from IQVIA HOLDINGS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Iqvia Holdings (IQV), a healthcare services company for drugmakers, has risen 79% since its April low. The stock, up 18.8% YTD, reports Q3 earnings on Oct. 27. Analysts discuss AI's impact, growth prospects, and technical indicators.
3 min readAzenta reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B revenue, up 8.7% YoY, exceeding expectations. UFP Technologies reported $174M revenue, up 15.1% YoY, with the largest analyst estimate beat. West Pharmaceutical Services reported $872.3M revenue, up 13.8% YoY, topping expectations. All stocks have seen post-earnings gains.
2 min readStifel raised its price target for IQVIA (NYSE:IQV) to $303 from $276, citing an improving market backdrop and strong company performance. The stock is near its 52-week high and has surged 48.72% over the past six months. Multiple analysts have raised their price targets and maintained buy ratings, highlighting IQVIA's growth prospects and strong data infrastructure.
1 min readJPMorgan raised its price target for IQVIA Holdings to $295 from $285. The company's stock is currently trading at $260.68, with a 5-day change of -0.58% and a 1st Jan change of +0.27%.
1 min readItaly's data protection authority fined IQVIA €7M for GDPR violations, ruling that a database of 1M patient records was not anonymous. The regulator found that unique codes and detailed health data allowed patient re-identification. IQVIA, which handles 1.2B patient records globally, was also found to be the data controller, not a processor, increasing its liability. The company must comply within 120 days or transfer anonymization responsibilities to doctors.
3 min readIQVIA (NYSE:IQV) introduced AI models to predict clinical trial outcomes, combining its proprietary data with NVIDIA and AWS technologies. The models aim to optimize trial design and predict outcomes, with 85% accuracy in initial tests. This expands IQVIA's predictive clinical development approach, potentially benefiting its life sciences and healthcare clients.
1 min readIQVIA Inc. launched IQVIA Explorer, a real-time commercial intelligence tool for life sciences. The product connects data, analytics, and workflows to provide insights for commercial decisions. Investors should monitor customer adoption and revenue impact in future earnings reports, according to AI Analyst.
1 min readAzenta reported Q2 revenues of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B in revenues, up 8.7% YoY, exceeding expectations. Charles River Laboratories reported $1.00B in revenues, down 2.7% YoY, but beating estimates. Repligen reported $204.1M in revenues, up 11.9% YoY, also beating estimates. All stocks have seen significant gains since reporting.
2 min readUBS raised its price target for IQVIA from $240 to $345, maintaining a buy rating. The company's stock is currently trading at $270.77. RBC Capital Markets also noted a positive outlook for IQVIA due to accelerating drug approvals.
1 min readIQVIA HOLDINGS INC. (IQV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement Notes Offering and Notes Indenture On September 23, 2026, IQVIA Inc. (the “Issuer”), a wholly owned subsidiary of IQVIA Holdings Inc., completed the issuance and sale of $2,000,000,000 in gross proceeds of 6.375% senior notes d
2 min read
